GKOSGlaukos Corporation

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Thomas W. Burns

Location

California, USA

Exchange

NYSE

Website

https://glaukos.com

Summary

Glaukos Corporation focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Company Info

CEO

Thomas W. Burns

Location

California, USA

Exchange

NYSE

Website

https://glaukos.com

Summary

Glaukos Corporation focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

AI Insights for GKOS
5 min read

Quick Summary

Glaukos Corporation is a medical equipment and ophthalmology company headquartered in San Clemente, California. The company develops and commercializes therapies for glaucoma, corneal disorders, and retinal diseases. Its business is focused on ophthalmic devices, drug-delivery technologies, and related procedures that are used by eye-care specialists. Glaukos sells through a direct sales organization as well as through distributors in the United States and international markets. Its main customers include ophthalmologists, eye surgery centers, hospitals, clinics, and health systems that treat patients with chronic eye diseases. The company is especially associated with minimally invasive glaucoma treatment and newer corneal health therapies.

Strengths

•

Glaukos’s primary strength is its specialized focus on ophthalmology and its reputation for innovation in glaucoma and corneal therapies.

•

The company operates in attractive medical markets where chronic disease prevalence, aging populations, and demand for better treatment options support long-term growth.

•

Its recent revenue acceleration suggests strong commercial execution in the United States, especially for iDose TR and Epioxa.

•

The company has a direct sales organization and distributor relationships, which help it reach ophthalmologists and eye-care providers across multiple markets.

•

Glaukos also benefits from exposure to a broader ophthalmology market that is expected to grow meaningfully over the next several years.

Key Risks

•

Glaukos faces competitive risks from large ophthalmology companies such as Alcon, AbbVie, Santen, Bausch + Lomb, Novartis, Johnson & Johnson Vision, and others.

•

These companies may have greater financial resources, stronger distribution networks, broader product portfolios, and established relationships with physicians.

•

The company also faces execution risk because its valuation depends on sustained growth from key products such as iDose TR and Epioxa.

•

Litigation expenses are a notable risk because recurring legal costs can pressure profitability and make adjusted results less comparable to GAAP performance.

What to Watch

During the most recent reported quarter, Glaukos delivered strong revenue performance, with total revenue of about $211 million.
The company’s U.S.
Glaucoma business was a major contributor, with iDose TR highlighted as an important driver of growth.
Corneal Health also contributed meaningfully, with Epioxa cited as a product supporting segment expansion.
International glaucoma performance declined, which shows that growth was not evenly distributed across all geographies and product lines.
Margins improved during the quarter, but GAAP profit remained slim, with net income around $2 million and diluted EPS of $0.03.
The company also raised full-year 2026 sales guidance and communicated a 2027 revenue target of $1 billion, which was a major investor event.

Price Drivers

•

Glaukos’s stock price is being driven primarily by rapid revenue growth, improved guidance, and investor expectations for continued adoption of its newer ophthalmology products.

•

Recent news reported that Q3 sales rose 58% to $211 million, helped by strong U.S.

•

Glaucoma performance from iDose TR and Corneal Health growth from Epioxa.

•

The company raised 2026 sales guidance to $775 million to $785 million and set a $1 billion 2027 revenue target, which contributed to a reported 31% share-price increase.

•

The stock also reflects a very high growth valuation, with enterprise value to revenue above 20 and price to book around 20, so investor sentiment can change quickly if growth slows.

•

Broader small-cap and medical technology trends may also affect the stock, especially if interest-rate expectations shift or investors rotate into high-growth healthcare names.

•

Litigation costs, GAAP profitability, reimbursement developments, and margin trends are additional factors that can influence the price.

Recent News

•

Recent news about Glaukos was dominated by a strong quarterly sales update and upgraded long-term revenue expectations.

•

The company reportedly raised 2026 sales guidance to $775 million to $785 million and set a $1 billion revenue target for 2027.

•

Shares rose sharply, reportedly gaining 31% after the update, as investors reacted to the faster growth outlook.

•

Q3 sales increased 58% to $211 million, driven by U.S.

•

Glaucoma growth from iDose TR and Corneal Health growth from Epioxa.

•

The news also noted that international glaucoma declined, which remains an area to monitor.

•

Margins improved, but GAAP profit was still slim and adjusted results excluded recurring legal costs, so investors are also focused on the quality of earnings.

Market Trends

•

The broader ophthalmology market is benefiting from aging populations, rising prevalence of glaucoma, corneal disease, retinal disease, myopia, and other eye conditions.

•

Industry reports cited in the news project strong growth for ophthalmology, with the market expected to expand substantially through 2030.

•

New technologies such as AI-enabled diagnostics, improved drug delivery, remote care, and personalized treatment are changing how eye diseases are detected and treated.

•

Cell and gene therapies are also expected to transform ophthalmology over time, especially for degenerative eye diseases such as AMD, glaucoma, and retinitis pigmentosa.

•

Competition is increasing as large medical device and pharmaceutical companies invest more heavily in eye care.

•

Small-cap market trends and potential interest-rate cuts may also influence Glaukos because growth-oriented medical technology companies can be sensitive to investor risk appetite.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on GKOS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@kewur 1 year ago

US Stocks Rebound as Undervalued Banks Catch Attention Amid China News

US Stocks Rebound as Undervalued Banks Catch Attention Amid China News

post thumbnail

No more topics to show